---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-002355"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-04-09T23:59:59+00:00"
generated_at: "2026-05-23T18:16:59.761707+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phio gets SMC nod to advance PH-762 skin cancer trial to 4th dose cohort

## Summary
- Safety Monitoring Committee recommended dose escalation to fourth cohort in Phase 1b trial (NCT06014086).
- Third cohort (3 patients with cutaneous squamous cell carcinoma): no serious AEs, no dose-limiting toxicities.
- Prior second cohort (4 patients): 2 complete responses (100% tumor clearance), 1 partial (90% clearance) at Day 36.
- PH-762 is an intratumoral siRNA compound targeting cutaneous SCC, melanoma, and Merkel cell carcinoma.

## SEC filing metadata
- accession: 0001683168-25-002355
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316825002355/0001683168-25-002355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316825002355/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-002355
- JSON: https://secwatch.observer/filing/0001683168-25-002355.json
- Plain text: https://secwatch.observer/filing/0001683168-25-002355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.